Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure

  • J Med Chem. 2020 Sep 10;63(17):9003-9019. doi: 10.1021/acs.jmedchem.9b02101.
Yoshikazu Asahina  1 Nicholas R Wurtz  2 Kazuto Arakawa  1 Nancy Carson  2 Kiyoshi Fujii  1 Kazunori Fukuchi  1 Ricardo Garcia  2 Mei-Yin Hsu  2 Junichi Ishiyama  1 Bruce Ito  3 Ellen Kick  2 John Lupisella  2 Shingo Matsushima  1 Kohei Ohata  1 Jacek Ostrowski  2 Yoshifumi Saito  1 Kosuke Tsuda  1 Francisco Villarreal  3 Hitomi Yamada  1 Toshikazu Yamaoka  1 Ruth Wexler  2 David Gordon  2 Yasushi Kohno  1
Affiliations
  • 1. Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd., 2399-1, Nogi, Nogi-Machi, Shimotsuga-Gun, Tochigi 329-0114, Japan.
  • 2. Bristol-Myers Squibb Research and Development, P.O. Box 5400, Princeton, New Jersey 08534, United States.
  • 3. Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.
Abstract

Formyl peptide receptor 2 (FPR2) agonists can stimulate resolution of inflammation and may have utility for treatment of diseases caused by chronic inflammation, including heart failure. We report the discovery of a potent and selective FPR2 agonist and its evaluation in a mouse heart failure model. A simple linear urea with moderate agonist activity served as the starting point for optimization. Introduction of a pyrrolidinone core accessed a rigid conformation that produced potent FPR2 and FPR1 agonists. Optimization of lactam substituents led to the discovery of the FPR2 selective agonist 13c, BMS-986235/LAR-1219. In cellular assays 13c inhibited neutrophil chemotaxis and stimulated macrophage phagocytosis, key end points to promote resolution of inflammation. Cardiac structure and functional improvements were observed in a mouse heart failure model following treatment with BMS-986235/LAR-1219.

Products